

Drug Monograph

Drug/Drug Class: **Lo Minastrin FE (norethindrone acetate, ethinyl estradiol, ferrous fumarate) tablets / Estrogen/Progestin Combination Oral Contraceptive**

Prepared for: MO HealthNet

Prepared by: Xerox Heritage, LLC

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
Dosage Forms:	Each Lo Minastrin FE package contains 24 blue chewable active tablets that contain 1 mg norethindrone acetate and 10 mcg ethinyl estradiol, 2 white active tablets that contain 10 mcg ethinyl estradiol, 2 brown inactive tablets that contain 75 mg of ferrous fumarate.
Manufacturer:	Warner Chilcott Company LLC Fajardo, PR 00738
Indications:	Lo Minastrin FE is an estrogen/progestin combination oral contraceptive indicated for use by women to prevent pregnancy.
Costs:	\$2.96 per tablet of Lo Minastrin FE. Wholesale Acquisition Cost
Summary of Findings:	MO HealthNet Division recommends Open Access status for this product.
Status Recommendation:	<input type="checkbox"/> Prior Authorization (PA) Required <input checked="" type="checkbox"/> Open Access <input type="checkbox"/> Fiscal Edit <input type="checkbox"/> PDL
Type of PA Criteria:	<input type="checkbox"/> Increased Risk of ADE <input type="checkbox"/> Preferred Agent <input type="checkbox"/> Appropriate Indications <input checked="" type="checkbox"/> No PA Required

Prepared By: Malena Jost, Pharm.D. Candidate
Date: October 14, 2013